- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Smaller, independent equity research firms are starting to cause bigger waves in the marketplace, but is the information really that valuable?
Despite tepid market reaction, and analyst skepticism, there might be some upside for TMO.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.